Cargando…

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview

OBJECTIVES: This study provides an overview of the largest and longest-running colonoscopic surveillance program for colorectal cancer (CRC) in patients with long-standing ulcerative colitis (UC). METHODS: Data were obtained from medical records, endoscopy, and histology reports. Primary end points...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Chang-Ho Ryan, Rutter, Matthew D, Askari, Alan, Lee, Gui Han, Warusavitarne, Janindra, Moorghen, Morgan, Thomas-Gibson, Siwan, Saunders, Brian P, Graham, Trevor A, Hart, Ailsa L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517513/ https://www.ncbi.nlm.nih.gov/pubmed/25823771 http://dx.doi.org/10.1038/ajg.2015.65

Ejemplares similares

Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2019)

Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
por: Choi, Chang-ho Ryan, et al.
Publicado: (2015)

Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool
por: Curtius, Kit, et al.
Publicado: (2022)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Evolutionary history of human colitis-associated colorectal cancer
por: Baker, Ann-Marie, et al.
Publicado: (2019)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy
por: Kayes, Tahrima, et al.
Publicado: (2021)

Treatment-refractory ulcerative colitis responsive to indigo naturalis
por: Saiki, Julie P, et al.
Publicado: (2021)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer
por: Corfe, Bernard M, et al.
Publicado: (2015)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
por: Johansson, Malin E V, et al.
Publicado: (2014)

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
por: He, Xiaolong, et al.
Publicado: (2021)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
por: van der Post, Sjoerd, et al.
Publicado: (2019)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Acute appendicitis and ulcerative colitis: a population-based sibling comparison study
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
por: Magro, Fernando, et al.
Publicado: (2023)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature
por: Scioli, Maria Giovanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eprkbqn70jane01ei0t03ooqkk